Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (704)	$ (2,396)	$ (1,626)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	700	861	1,100
Deferred income taxes	(3)	(454)	(116)
Government and other legal settlements and related costs	11	9	16
Stock-based compensation expense	13	24	46
Impairment of hospitals sold or held for sale		6	8
Impairment and (gain) loss on sale of businesses, net	668	2,123	1,919
(Gain) loss from early extinguishment of debt	(31)	40	30
Gain on sale of investments in unconsolidated affiliates			(94)
Other non-cash expenses, net	38	35	31
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	31	732	(96)
Supplies, prepaid expenses and other current assets	16	(33)	25
Accounts payable, accrued liabilities and income taxes	(163)	(69)	(137)
Payment of HMA legal settlement	(266)
Other	(36)	(105)	31
Net cash provided by operating activities	274	773	1,137
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(26)	(6)	(123)
Purchases of property and equipment	(527)	(564)	(744)
Proceeds from disposition of hospitals and other ancillary operations	405	1,692	143
Proceeds from sale of property and equipment	8	7	15
Purchases of available-for-sale securities and equity securities	(78)	(125)	(505)
Proceeds from sales of available-for-sale securities and equity securities	114	208	464
Proceeds from sale of investments in unconsolidated affiliates			403
Distribution from Quorum Health Corporation			1,219
Increase in other investments	(141)	(143)	(242)
Net cash (used in) provided by investing activities	(245)	1,069	630
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(1)	(5)	(6)
Deferred financing costs and other debt-related costs	(96)	(66)	(26)
Proceeds from noncontrolling investors in joint ventures	3	5
Redemption of noncontrolling investments in joint ventures	(31)	(6)	(19)
Distributions to noncontrolling investors in joint ventures	(96)	(100)	(92)
Proceeds from sale-lease back			159
Borrowings under credit agreements	28	841	4,879
Issuance of long-term debt	1,033	3,100
Proceeds from ABL and receivables facility	797	105	107
Repayments of long-term indebtedness	(2,033)	(5,391)	(6,715)
Net cash used in financing activities	(396)	(1,517)	(1,713)
Net change in cash and cash equivalents	(367)	325	54
Cash and cash equivalents at beginning of period	563	238	184
Cash and cash equivalents at end of period	196	563	238
Supplemental disclosure of cash flow information:
Interest payments	(936)	(852)	(930)
Income tax refunds (payments), net	$ 19	$ (4)	$ 16